Innoviva Inc (INVA) — closed signal from May 25, 2026
Partial Published before the outcome was known, scored automatically when the window closed on August 23, 2026 — -6.2% at the close.
Predicted vs. what happened
What happened
Reached 38% of the predicted growth at its peak, without hitting the target.
The thesis — published May 25, 2026
A value-focused healthcare company that earns recurring money from royalties and has a solid balance sheet. Recent industry commentary supports that the royalty income is reliable. Trading is thin, sentiment is negative, and many traders are betting against it, so overall conviction is tempered. Short-term upside exists if current price support holds.
Primary drivers
- Regular royalty payments provide steady cash generation
- Recent commentary supports the durability of royalty income
- A strong balance sheet helps withstand price declines
- Low price relative to cash flow allows for possible re-rating
How it played out
INVA: the target was never reached
Lyra published INVA at $22.46 with 20% expected growth and a $26.95 target. The thesis pointed to recurring royalty payments, commentary supporting durable royalty income, a strong balance sheet, and a low price relative to cash flow. It also noted thin trading, negative sentiment, and heavy short interest, which tempered conviction.
Inside the window, INVA peaked at $24.17 on June 24, a 7.6% gain. The stock stayed below the $26.95 target and never reached it. By August 23, it had fallen to $21.07, below the published price and entry zone. The thesis partially played out at the peak, but the expected 20% growth missed.
What happened during the window
On June 16, Innoviva Specialty Therapeutics announced an exclusive distribution and licensing agreement with Dr. Reddy's for XACDURO in selected international markets. On June 18, Innoviva's subsidiary Nortiva Bio announced its launch to develop long-acting oral medicines.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.